The breast cancer resistance protein (BCRP, ABCG2) is an efflux transporter that removes xenobiotics that cross the placenta back to the maternal circulation, thereby limiting exposure of the fetus to drugs and chemicals. Currently, variability of BCRP expression within the placenta is not known. Ten placentas were collected from healthy women undergoing elective Cesarean sections at term. Villous samples were dissected in defined regions (medial, intermediate, and peripheral) and BCRP mRNA and protein were quantified. There were no regional differences in mRNA expression of housekeeping genes (GAPDH, RPL13a, PRL, 18S). GAPDH had the lowest correlation with BCRP Ct values and was used for BCRP mRNA normalization. No differences in placental BCRP mRNA and protein were observed among the sample sites (<20% variability). Sampling site does not affect the expression of BCRP, supporting the utility of single site sampling protocols to assess the interindividual regulation of this transporter in human placentas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946646 | PMC |
| http://dx.doi.org/10.1016/j.reprotox.2013.11.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interaction of Phyllanthus amarus extract and its lignans with human xenobiotic receptors, drug metabolizing enzymes and drug transporters.
J Ethnopharmacol
January 2025
National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, MS, 38677, United States; Department of Bio-Molecular Sciences, School of Pharmacy, The University of Mississippi, MS, 38677, United States. Electronic address:
Ethnopharmacological Relevance: Phyllanthus amarus is ethnomedicinally used to treat gallbladder stones, kidney stones and chronic liver diseases. P. amarus is gaining popularity as an ingredient in many botanical dietary supplements.
View Article and Find Full Text PDFUpregulation of P-Glycoprotein and Breast Cancer Resistance Protein Activity in Newly Developed in Vitro Rat Blood-Brain Barrier Spheroids Using Advanced Glycation End-Products.
Biol Pharm Bull
November 2024
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.
The blood-brain barrier (BBB) is a dynamic interface controlling the compound translocation between the blood and the brain, thereby maintaining neural homeostasis. There is cumulative evidence that BBB impairment during diabetes mellitus (DM) takes part in the progression of cognitive dementia. As tight junction proteins and ATP-binding cassette (ABC) transporters regulate substance exchange between the circulating blood and brain, the expression and function of these molecules under DM should be fully clarified.
View Article and Find Full Text PDFModulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition.
Arch Pharm Res
November 2024
Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
Human antigen R (HuR), an RNA-binding protein, is implicated in regulating mRNA stability and translation in cancer, especially in triple-negative breast cancer (TNBC), a highly aggressive form. CRISPR/Cas9-mediated HuR knockout (HuR CRISPR) presents a promising genetic therapeutic approach, but it encounters transfection limitations. Docetaxel (DTX), an effective cytotoxic agent against metastatic breast cancer (BC), faces challenges related to vehicle-associated adverse events in DTX formulations.
View Article and Find Full Text PDFIL-17A activates JAK/STAT signaling to affect drug metabolizing enzymes and transporters in HepaRG cells.
Mol Immunol
November 2024
Department of Pharmacy, People's Hospital of Peking University, Beijing, China. Electronic address:
Article Synopsis
- IL-17A is a pro-inflammatory cytokine linked to autoimmune disorders and affects liver drug metabolism, though its exact impact on drug-metabolizing enzymes and transporters is not well understood.
- This study investigates how IL-17A influences DMETs (drug-metabolizing enzymes and transporters) in liver cells (HepaRG) through specific molecular techniques, revealing it inhibits the expression of multiple key enzymes and transporters.
- The findings suggest that altered DMET regulation due to IL-17A in immune-related conditions, like psoriasis, may lead to changes in how drugs are processed in the body, potentially causing unexpected drug interactions in patients.
A close examination of BCRP's role in lactation and methods for predicting drug distribution into milk.
CPT Pharmacometrics Syst Pharmacol
November 2024
Division of Pharmacy and Optometry, Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
Breastfeeding is the most complete nutritional method of feeding infants, but several impediments affect the decision to breastfeed, including questions of drug safety for medications needed during lactation. Despite recent FDA guidance, few labels provide clear dosing advice during lactation. Physiologically based pharmacokinetic modeling (PBPK) is well suited to mechanistically explore pharmacokinetics and dosing paradigms to fill gaps in the absence of extensive clinical studies and complement existing real-world data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!